Compare CGBD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGBD | ABUS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.2M | 848.8M |
| IPO Year | N/A | 2008 |
| Metric | CGBD | ABUS |
|---|---|---|
| Price | $10.85 | $4.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $12.92 | $5.00 |
| AVG Volume (30 Days) | 513.8K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 14.42% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.80 | $239.71 |
| P/E Ratio | $10.36 | ★ $5.28 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $10.62 | $3.04 |
| 52 Week High | $14.32 | $5.10 |
| Indicator | CGBD | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 57.10 |
| Support Level | $10.68 | $4.16 |
| Resistance Level | $12.17 | $4.60 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 16.82 | 67.81 |
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.